US FDA Needs Plan For Addressing Inspection Backlog Post-COVID, GAO Says
Executive Summary
FDA also should more fully explore using alternatives to on-site inspections the pandemic prevents it from conducting, said Mary Denigan-Macauley, director of GAO’s health care office.